
City Therapeutics is looking for a passionate Senior/Principal Scientist CMC Process Development and Manufacturing who will be responsible for leading drug substance process development projects for our programs at different stages, with a focus on process development and process characterization for oligonucleotides with novel chemical modifications. The role involves overseeing development projects, supporting non-GMP and GMP drug substance manufacturing, and collaborating with various cross-functional teams both internal and external. The ideal candidate must have strong problem-solving skills, extensive knowledge of oligonucleotide chemistry, and proven experience in oligonucleotide process development. This position is fully onsite and will be primarily located at our Cambridge, MA location.
Key Responsibilities
Qualifications:
Preferred Skills:
Please note this role is required to be on-site at our offices in Cambridge, MA (5 days a week).
Compensation: The base salary range provided reflects our current estimate of what we anticipate paying for this position. Your actual base salary will be based on several factors, including relevant skills, experience, internal equity, relevant education or training and market dynamics. In addition, this role is eligible for an annual cash bonus and equity compensation. City Therapeutics offers a comprehensive and competitive benefits package including medical, dental, vision, life insurance, health and dependent care FSA accounts, HSA/HRA accounts with company contributions, in addition to a 401(k) with competitive company match. Per Year Salary Range dependent on level: $136,000-$185,000.
City Therapeutics is accepting resumes/CVs from direct applicants only. Recruitment agency submissions will not be accepted at this time.
City Therapeutics is an Equal Opportunity and Affirmative Action employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership, or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing); or any other characteristic protected by law.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.